Funding for this research was provided by:
Foundation for the National Institutes of Health (R01NS103940, R01NS084398)
National Science Foundation (CHE-1610964)
U.S. Army Medical Research Acquisition Activity (W81XWH-17-1-0455)
Article History
Received: 19 January 2021
Accepted: 15 March 2021
First Online: 14 April 2021
Declarations
:
: Not applicable.
: Not applicable.
: DJB has a financial interest in Meru Biotechnologies, a company formed to commercialize FSA and the CIR. The other authors declare that they have no competing financial interests.